Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Bubs Australia Ltd. ( (AU:BUB) ) is now available.
Bubs Australia Ltd. has submitted its New Infant Formula Submission to the US FDA, marking a crucial step towards securing permanent regulatory approval in the US market. This move is part of Bubs’ strategy to solidify its position in the US, its largest market, and is expected to enhance its growth prospects. The successful completion of a large-scale clinical trial in the US underscores Bubs’ technical and operational capabilities, positioning it as a credible global manufacturer in the dairy industry.
The most recent analyst rating on (AU:BUB) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
More about Bubs Australia Ltd.
Bubs Australia Ltd. operates in the dairy industry, focusing on producing infant milk formulas. The company offers products such as goat milk formula, 365-day grass-fed formula, and essential formula, with a significant market presence in the United States.
Average Trading Volume: 1,879,907
Technical Sentiment Signal: Hold
Current Market Cap: A$142.9M
See more insights into BUB stock on TipRanks’ Stock Analysis page.